Soligenix, Inc. (SNGX)

NCM – Real Time Price. Currency in USD

0.41

+0.01 (3.80%)

At close: Jun 26, 2026, 4:00 PM EDT

0.41

-0.00 (-1.07%)

After-hours: Jun 26, 2026, 7:12 PM EDT

08.06.2026

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due June 12, 2026.

26.05.2026

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an Orthoebolavirus, will require new vaccine formulation efforts.

08.05.2026

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended March 31, 2026.

28.04.2026

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Data Monitoring Committee completed the interim efficacy analysis of its pivotal Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial evaluating HyBryte™ (Synthetic Hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).

02.04.2026

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor ® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy.

31.03.2026

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trial PRINCETON, N.J., March 31, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2025.

26.03.2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.

Videos

No Data

There is no data to display

Press releases

08.06.2026

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

26.05.2026

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

08.05.2026

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

28.04.2026

Soligenix, Inc. (SNGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Soligenix, Inc. (SNGX)

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Videos

No Data

Press releases

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Videos

No Data

Press releases

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Search stocks

Soligenix, Inc. (SNGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Soligenix, Inc. (SNGX)

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Videos

No Data

Press releases

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Videos

No Data

Press releases

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma